Express Scripts Holding Co (NASDAQ:ESRX) has been assigned a consensus rating of “Hold” from the twenty-two brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, fourteen have given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $89.46.

ESRX has been the subject of several analyst reports. Zacks Investment Research cut Express Scripts from a “hold” rating to a “sell” rating in a report on Monday, July 23rd. BidaskClub upgraded Express Scripts from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. William Blair upgraded Express Scripts from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 1st. Royal Bank of Canada raised their price objective on Express Scripts to $94.00 and gave the company an “outperform” rating in a report on Monday, August 27th. Finally, ValuEngine upgraded Express Scripts from a “hold” rating to a “buy” rating in a report on Monday, September 17th.

Shares of NASDAQ ESRX opened at $96.90 on Friday. The stock has a market capitalization of $55.06 billion, a PE ratio of 11.38, a P/E/G ratio of 1.23 and a beta of 0.89. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.77 and a quick ratio of 0.65. Express Scripts has a fifty-two week low of $60.63 and a fifty-two week high of $100.43.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.01. The company had revenue of $25.56 billion during the quarter, compared to analysts’ expectations of $25.11 billion. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. Express Scripts’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.51 EPS. As a group, sell-side analysts forecast that Express Scripts will post 9.08 EPS for the current fiscal year.

In related news, Director Mahon Thomas P. Mac sold 5,234 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $99.50, for a total value of $520,783.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.79% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Kentucky Retirement Systems acquired a new stake in Express Scripts during the third quarter worth approximately $4,673,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its position in Express Scripts by 3.0% during the third quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 1,209,500 shares of the company’s stock worth $114,915,000 after acquiring an additional 35,000 shares during the last quarter. Alpine Global Management LLC acquired a new stake in Express Scripts during the third quarter worth approximately $4,751,000. Fieldpoint Private Securities LLC lifted its position in Express Scripts by 40.1% during the third quarter. Fieldpoint Private Securities LLC now owns 2,095 shares of the company’s stock worth $199,000 after acquiring an additional 600 shares during the last quarter. Finally, IndexIQ Advisors LLC lifted its position in Express Scripts by 8.0% during the third quarter. IndexIQ Advisors LLC now owns 495,311 shares of the company’s stock worth $47,059,000 after acquiring an additional 36,889 shares during the last quarter. Institutional investors and hedge funds own 83.15% of the company’s stock.

About Express Scripts

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Read More: Bond

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.